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INTRODUCTION
The meningioma (ME) was originally 
described by Virchow in 1863 as a tumor 
originating from meningothelial cells that 
are usually found within leptomeninges and 
the choroid plexi of the ventricles, with a 
preference for the supratentorial area.1 Any 
area that is covered by the leptomeninges, 
however, is potentially a site of origin for me-
ningiomas. The first report of an exclusively 
intracanalicular (IC) ME has been attributed 
to Singh et al. in 1975.2 Since then, about 15 
ICME have been described in the English 
medical literature.1,3
CASE STUDY
MJRC, age 51 years, female, white, 
presented constant tinnitus for six months and 
left hypoacusis for four months. The otorhino-
laryngological and neurological exams were 
within normal limits, except for unilateral left 
hearing loss (PTA - 27.5dB; discrimination 
- 60%). Magnetic resonance imaging showed 
a tumor in the internal acoustic canal, an 
image suggesting a vestibular schwannoma 
(VS). Surgery done through a middle fossa 
approach revealed a tumor that was redder 
and more adhered than usual, measuring 
about 10x5mm. It was located atypically in the 
internal acoustic canal - between the nerves 
- rather than in the classical posterior position. 
Facial paralysis House-Brackmann grade IV 
presented postoperatively.
Histology reported a tumor compati-
ble with meningothelial meningioma, which 
was confirmed by immunohistochemistry 
(S-100 - negative; EMA - positive). Audiome-
try was done 15 days later, demonstrating 
that hearing was preserved (PTA - 62.5dB). 
The patient recovered from facial paralysis, 
which had decreased to grade II six months 
postoperatively.
DISCUSSION
Differentiating MEs from VSs may be 
difficult when MEs are exclusively IC. Both 
tumors affect similar age groups (45-55 yrs) 
and predominate in females. They also pre-
sent with similar signs and symptoms, such 
as hearing loss and tinnitus.1 Facial paralysis 
may occur in up to 27% of ICME cases; it is, 
however, less common in ICVSs (about 3%).1,3 
Radiological differentiation between both 
tumors is generally not possible.1,3
ICME surgery has certain peculiarities. 
Compared to ICVSs, ICMEs tend to adhere 
more and to be more vascularized; they may 
also occupy various portions of the internal 
acoustic canal.1 Such lack of predictability in 
the location of ICME and its relation with the 
VII and VIII cranial nerves may significantly 
increase the difficulty of surgery; the facial 
nerve may be displaced 
by the tumor to any of the 
quadrants in the internal 
acoustic canal, increasing 
the possibility of iatrogenic 
injuries.1,3 We defended and 
demonstrated the possibility 
of preserving postoperative 
hearing, as defined by the 
“Committee on Hearing and 
Equilibrium of the American 
Academy of Otolaryngology 
- Head & Neck Surgery”.4 
The real possibility of pre-
serving hearing, however, 
is still uncertain in ICME 
cases, given the  paucity of 
case reports.
Immunohistoche-
mistry is useful in differen-
tiating these tumors. MEs 
may express both epithelial 
and mesenchymal markers, 
reflecting their double embryological origin or 
mesenchymal cell totipotentiality. Many ma-
rkers have been used, although there is wide 
variation of results in the literature, which may 
be credited to differences in methodology.5 
The “epithelial membrane antigen” (EMA) is 
generally strongly positive in MEs (84%) and 
negative or weakly positive and with a focal 
pattern in VSs. Protein S-100 is not a specific 
marker for neuroectodermal tissue; it may be 
positive in 28% of MEs.5 Vimentin is positive 
in about 95% of MEs.5 Table 1 shows the main 
immunohistochemical findings in posterior 
fossa tumors, based on studies by Winek6 and 
Radley.5 Electron microscopic ultra-structural 
studies should be reserved for difficult cases 
not clarified by immunohistochemistry, given 
the high cost and the technical difficulties of 
this method.
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Table 1. Main immunoreactive features for differentiating poste-
rior fossa tumors.
TUMOR Vimentin EMA keratin
S-100 
protein
GFAP
Meningioma + + +/- (a) +/- (b) -
Schwannoma + +/- (c) - + -
glioma + - - + +
carcinoma - + + +/- -
melanoma + - - + -
cordoma + + + + -
(a)  - positive in secretory meningiomas
(b)  - positive in 15%
(c)  - in general weak and focal when positive
Key: EMA - epithelial membrane antigen; GFAP - glial fibrillary 
acidic protein.
